MedPath

Oculis Price Target Increased by BofA Following Promising Phase 2 Trial Results

BofA has raised Oculis's price target from $23 to $31, maintaining a Buy rating, after the company reported positive Phase 2 results from the ACUITY trial for OCS-05 therapy in treating acute optic neuritis (AON). The trial demonstrated both safety and promising efficacy, leading to an increased modeled AON contribution from $10M to $330M.

BofA has increased the price target for Oculis (OCS) from $23 to $31, while keeping a Buy rating on the shares. This adjustment follows the company's announcement of Phase 2 results from the ACUITY trial, which assessed the safety and efficacy of short-term OCS-05 therapy in patients suffering from acute optic neuritis (AON). According to BofA, the trial has successfully established that OCS-05 can be dosed safely and has shown promising efficacy.
Oculis is now planning to meet with regulators to outline a development path, which is expected to include a single, pivotal trial for this rare ocular condition that can result in permanent visual impairment. Following these developments, BofA has also boosted its modeled AON contribution from $10M to $330M, reflecting a higher assumed probability of success.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Stoke Therapeutics Receives Buy Rating Based on Strong Phase 3 Trial Design and Early Results

Stoke Therapeutics has been given a Buy rating by analyst Andrew Fein from H.C. Wainwright, supported by the promising design of its Phase 3 trial for zorevunersen and positive early results in reducing seizure frequency in Dravet syndrome patients.

Denali Therapeutics' ALS Trial Fails to Meet Endpoints, BofA Adjusts Stock Target

Denali Therapeutics' DNL343, an eIF2B inhibitor, failed to meet primary and key secondary endpoints in a Phase 2/3 trial for amyotrophic lateral sclerosis (ALS) at 24 weeks.
BofA Securities reduced Denali's stock target to $30 from $34, removing DNL343 from their valuation model due to the uncertainty of the drug's future development.

Caribou Biosciences Price Target Increased by Brookline

Brookline Capital Markets has raised the price target for Caribou Biosciences (CRBU) to $34 from $26, maintaining a Buy rating. The adjustment follows plans for a CB-010 phase III trial in 2025, pending positive data on patient outcomes.

Oculis' OCS-05 Shows Promise in Phase 2 Trial for Acute Optic Neuritis

Oculis Holding AG's OCS-05 met the primary safety endpoint and achieved statistically significant results in key secondary efficacy endpoints in the ACUITY trial.
The Phase 2 trial evaluated OCS-05 in patients with acute optic neuritis, demonstrating a favorable safety profile compared to placebo.

Promising Clinical Results and Market Potential Drive Buy Rating for Oculis Holding

Oculis Holding (OCS) has been given a Buy rating by Stifel Nicolaus analyst Annabel Samimy, due to the promising clinical results of its drug OCS-05 in treating acute optic neuritis (AON). The drug showed significant improvements in anatomical and functional outcomes, with a positive safety profile and potential to reduce relapses in CNS inflammatory conditions. The FDA's clearance for its IND application supports its advancement into regulatory trials.

Oculis Holding Gains Buy Ratings Based on Promising Pipeline and Market Potential

Oculis Holding's OCS-01 is on track for NDA submission, potentially becoming the first once-daily, preservative-free steroid for post-operative ocular conditions.
The DIAMOND trials for OCS-01 in treating diabetic macular edema show promising patient enrollment, indicating strong market potential as a transformative eye drop.

Biofrontera's Ameluz Demonstrates High Efficacy in Phase III sBCC Trial

Biofrontera's Ameluz-PDT therapy met the primary endpoint, showing 65.5% success in complete clearance of superficial basal cell carcinoma (sBCC) lesions, compared to 4.8% with placebo.
The Phase III trial demonstrated that 75.9% of participants treated with Ameluz-PDT achieved complete histological clearance, versus 19% in the placebo group.

Alnylam's Amvuttra Poised to Become First-Line ATTR-CM Treatment

Alnylam Pharmaceuticals aims to establish Amvuttra as the preferred first-line treatment for ATTR amyloidosis with cardiomyopathy (ATTR-CM).
The company's strategy leverages positive HELIOS-B trial data and Amvuttra's convenient dosing regimen to gain market share.

FDA Lifts Partial Hold on Avidity Biosciences' Myotonic Dystrophy Drug, Stock Surges

The FDA has lifted a partial clinical hold on Avidity Biosciences' delpacibart etedesiran (AOC 1001), a drug targeting myotonic dystrophy type 1, allowing patient recruitment for the Phase 3 trial to resume.
Following the FDA's decision, Avidity Biosciences' stock (RNA) experienced a 0.53% increase, reaching $47.30, signaling positive investor response to the advancement of AOC 1001.

Travere Therapeutics' Filspari Receives Full FDA Approval for IgAN Treatment, Expanding Patient Access

Travere Therapeutics' Filspari gains full FDA approval for IgAN, removing prior UPCR restrictions and broadening treatment access.
KDIGO guidelines now recognize Filspari as a foundational IgAN therapy, supporting its role in managing the disease.

Reference News

[1]
Oculis price target raised to $31 from $23 at BofA
markets.businessinsider.com · Jan 6, 2025

BofA increased Oculis's (OCS) price target to $31 from $23, maintaining a Buy rating, following positive Phase 2 ACUITY ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy